ATOS
NASDAQAtossa Therapeutics Inc.
News · 26 weeks30+400%
2026-04-192026-10-11
Mix1190d
- Other5(45%)
- SEC Filings5(45%)
- Offering1(9%)
Latest news
25 items- SECSEC Form 8-K filed by Atossa Therapeutics Inc.8-K - ATOSSA THERAPEUTICS, INC. (0001488039) (Filer)
- PRAtossa Therapeutics Executes Contingent Value Rights Agreement Providing Shareholders Participation in Potential Priority Review Voucher ValueBoard declares one stapled CVR for each share of Atossa common stock outstanding as of October 19, 2026 record date or issued thereafterCVRs entitle holders to 25% of net proceeds from monetization of Atossa's first qualifying priority review voucher, subject to a $50 million aggregate payment capSEATTLE, Oct. 9, 2026 /PRNewswire/ -- Atossa Therapeutics, Inc. (NASDAQ:ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing innovative medicines in oncology and other areas of significant unmet need, today announced that it has entered into a definitive Stapled Contingent Value Rights Agreement (the "CVR Agreement") with VStock Transfer, LLC, as rights agent, imp
- PRAtossa Therapeutics Announces Plan to Issue Stapled CVR for Shareholders Tied to Potential Rare Pediatric Disease Priority Review VoucherShareholders would receive one CVR for each ATOS share held as of the record date or issued thereafterCVRs would entitle holders to 25% of net proceeds from monetization of Atossa's first qualifying priority review voucher, subject to a $50 million aggregate payment capSEATTLE, Sept. 29, 2026 /PRNewswire/ -- Atossa Therapeutics, Inc. (NASDAQ:ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing innovative medicines in oncology and other areas of significant unmet need, today announced that its Board of Directors has approved a plan to issue one contingent value right ("CVR") for each share of Atossa common stock to enable shareholders to share in a portion
- SECAtossa Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - ATOSSA THERAPEUTICS, INC. (0001488039) (Filer)
- PRAtossa Therapeutics CEO Dr. Steven Quay to Participate in ARDD 2026 Panel on Clinical Trials and Regulatory Pathways for Diseases of AgingPanel at Harvard University will explore translating evidence in diseases of aging into new therapeutics and regulatory pathwaysSEATTLE, Sept. 24, 2026 /PRNewswire/ -- Atossa Therapeutics, Inc. (NASDAQ:ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company, today announced that Steven Quay, M.D., Ph.D., Atossa's President and Chief Executive Officer, will participate as a panelist at the 13th Aging Research and Drug Discovery Meeting (ARDD 2026), being held October 1–3, 2026, at the David Rubenstein Treehouse at Harvard University in Boston, MA. The discussion will explore the translation of scientific ev
- SECAtossa Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - ATOSSA THERAPEUTICS, INC. (0001488039) (Filer)
- SECAtossa Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - ATOSSA THERAPEUTICS, INC. (0001488039) (Filer)
- PRAtossa Therapeutics Reports Second Quarter 2026 Financial Results and Provides a Corporate UpdateSEATTLE, Aug. 7, 2026 /PRNewswire/ -- Atossa Therapeutics, Inc. (NASDAQ:ATOS) (Atossa or the Company), a clinical-stage biopharmaceutical company developing novel therapies in oncology and other areas of high unmet clinical need, today announced its financial results and provided an update on recent corporate developments for the second quarter ended June 30, 2026. "During the quarter, we executed well across the business," stated Dr. Steven Quay, M.D., Ph.D., Atossa Therapeutics' President and Chief Executive Officer. "We continued to advance the scientific rationale for (Z)-endoxifen's potential in rare pediatric diseases, su
- SECSEC Form 10-Q filed by Atossa Therapeutics Inc.10-Q - ATOSSA THERAPEUTICS, INC. (0001488039) (Filer)
- PRAtossa Therapeutics Announces Publication of Novel (Z)-Endoxifen-Related Compounds Demonstrating Potent Anti-Cancer Activity in ER-Positive Breast CancerPeer-reviewed preclinical study published in npj Breast Cancer identifies new chemical entities with activity in ESR1-mutant models Findings suggest potential for combination with abemaciclibSEATTLE, July 28, 2026 /PRNewswire/ -- Atossa Therapeutics, Inc. (NASDAQ:ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapies in oncology and other areas of significant unmet clinical need, today announced the publication of a peer-reviewed preclinical study in npj Breast Cancer evaluating five novel chemical entities structurally related to (Z)-endoxifen. The study titled, "Novel (Z)-endoxifen-related new chemical entities exhibit potent anti-cancer ac
- PRAtossa Therapeutics Announces Presentation of Mechanism-Driven (Z)-Endoxifen Data in McCune-Albright Syndrome at AACR Special Conference on Rare CancersPreclinical Data Poster Highlights Dual Estrogen Receptor and PKC-β/AKT Pathway Modulation as a Potential Therapeutic Strategy for Estrogen-Driven Pathology in McCune-Albright syndromeSEATTLE, July 21, 2026 /PRNewswire/ -- Atossa Therapeutics, Inc. (NASDAQ:ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapies in oncology and other areas of significant unmet clinical need, today announced that a poster presentation titled "Dual estrogen receptor and PKC-β signaling modulation by (Z)-Endoxifen: A mechanism-driven therapeutic strategy for estrogen-driven pathology in McCune-Albright Syndrome" was presented at the AACR Special Conference in Canc
- ANALYSTRodman & Renshaw initiated coverage on Atossa Therapeutics with a new price targetRodman & Renshaw initiated coverage of Atossa Therapeutics with a rating of Buy and set a new price target of $12.00
- PRAtossa Therapeutics Announces Closing of Registered Direct Offering of up to $16.5 Million in Gross Proceeds$4.5 million upfront with up to an additional $12 million of potential aggregate gross proceeds upon exercise in full of warrantsSEATTLE, June 12, 2026 /PRNewswire/ -- Atossa Therapeutics, Inc. (NASDAQ:ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapies in oncology and other areas of high unmet clinical need, today announced the closing of its previously announced registered direct offering of 1,363,637 shares (the "Shares") of its common stock, par value $0.18 per share ("Common Stock") (or common stock equivalents in lieu thereof), Series A warrants to purchase up to 1,363,637 shares of Common Stock and short-term Series B warrants to pu
- SECSEC Form 424B5 filed by Atossa Therapeutics Inc.424B5 - ATOSSA THERAPEUTICS, INC. (0001488039) (Filer)
- SECAtossa Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits8-K - ATOSSA THERAPEUTICS, INC. (0001488039) (Filer)
- PRAtossa Therapeutics Announces Registered Direct Offering of up to $16.5 Million in Gross Proceeds$4.5 million upfront with up to an additional $12 million of potential aggregate gross proceeds upon exercise in full of warrantsSEATTLE, June 11, 2026 /PRNewswire/ -- Atossa Therapeutics, Inc. (NASDAQ:ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapies in oncology and other areas of high unmet clinical need, today announced that it has entered into a securities purchase agreement with institutional investors for the purchase and sale of 1,363,638 shares (the "Shares") of its common stock, par value $0.18 per share ("Common Stock") (or common stock equivalents in lieu thereof), Series A warrants to purchase up to 1,363,638 shares of Common
- PRAtossa Therapeutics Announces ASCO 2026 Abstracts Highlighting (Z)-Endoxifen Activity Across ESR1 Mutations and Ongoing EVANGELINE Phase 2 TrialPreclinical Data Abstract Demonstrates Robust Estrogen Receptor (ER) Inhibition in ESR1-Mutant Breast Cancer Models at Clinically Relevant ConcentrationsTrial-in-Progress Abstract Details Ongoing Phase 2 EVANGELINE Study of (Z)-Endoxifen Plus Goserelin as Neoadjuvant Therapy in Premenopausal Women With ER+/HER2- Breast CancerSEATTLE, May 27, 2026 /PRNewswire/ -- Atossa Therapeutics, Inc. (NASDAQ:ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapies in oncology and other areas of significant unmet medical need, today announced that two abstracts featuring (Z)-endoxifen have been accepted for presentation at the 2026 American Society of Clinic
- PRAtossa Therapeutics Announces Acceptance of Manuscript Highlighting Utrophin-Modulation Potential of (Z)-Endoxifen in Duchenne Muscular DystrophyReview article accepted for publication in Degenerative Neurological and Neuromuscular Disease and builds on Atossa's previously published Duchenne Muscular Dystrophy (DMD) researchSEATTLE, May 20, 2026 /PRNewswire/ -- Atossa Therapeutics, Inc. (NASDAQ:ATOS) (Atossa or the Company), a clinical-stage biopharmaceutical company developing novel therapies in oncology and other areas of significant unmet clinical need, today announced that the manuscript titled, "(Z)-Endoxifen as a Potential Modulator of Utrophin Pathways in Duchenne Muscular Dystrophy: A Mechanistic and Transcriptomic Perspective," has been accepted for publication in Degenerative Neurological and Neuromuscular Disease.
- INSIDERDirector Steinhart Richard I was granted 10,000 shares (SEC Form 4)4 - ATOSSA THERAPEUTICS, INC. (0001488039) (Issuer)
- INSIDERDirector Chen Shu-Chih was granted 10,000 shares (SEC Form 4)4 - ATOSSA THERAPEUTICS, INC. (0001488039) (Issuer)
- INSIDERDirector Remmel H. Lawrence was granted 10,000 shares, increasing direct ownership by 1,464% to 10,683 units (SEC Form 4)4 - ATOSSA THERAPEUTICS, INC. (0001488039) (Issuer)
- INSIDERDirector Finn Jonathan was granted 10,000 shares, increasing direct ownership by 600% to 11,666 units (SEC Form 4)4 - ATOSSA THERAPEUTICS, INC. (0001488039) (Issuer)
- INSIDERDirector Galli Stephen J was granted 10,000 shares, increasing direct ownership by 166,667% to 10,006 units (SEC Form 4)4 - ATOSSA THERAPEUTICS, INC. (0001488039) (Issuer)
- INSIDERDirector Cigler Tessa was granted 10,000 shares (SEC Form 4)4 - ATOSSA THERAPEUTICS, INC. (0001488039) (Issuer)
- PRAtossa Therapeutics to Host Virtual KOL Event Featuring Dr. Laura Esserman to Discuss Development of (Z)-Endoxifen in ER-Positive Breast CancerEvent to feature Dr. Laura Esserman, internationally recognized surgical oncologist, breast cancer expert, and founder and principal investigator of the I-SPY TrialsSEATTLE, May 14, 2026 /PRNewswire/ -- Atossa Therapeutics, Inc. (NASDAQ:ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapies in oncology and other areas of significant unmet medical need, today announced that it will host a virtual key opinion leader event focused on the evolving clinical and translational data supporting the development of (Z)-endoxifen, the Company's investigational selective estrogen receptor modulator/degrader, or SERM/D, as a potential next-generation endoc
ATOS FAQ
7 questionsWhat does Atossa Therapeutics Inc. do?
Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines in the areas of oncology and infectious diseases. The company's lead program is Endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It is also developing AT-301, a proprietary drug candidate for nasal administration in patients diagnosed with COVID-19; AT-H201, a drug candidate to improve lung function in COVID-19 patients; and immunotherapy/chimeric antigen receptor therapy programs for the treatment of breast cancer...Where does ATOS stock trade?
Atossa Therapeutics Inc. (ATOS) is listed on NASDAQ.What sector and industry is ATOS in?
Atossa Therapeutics Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Atossa Therapeutics Inc. go public?
Atossa Therapeutics Inc. (ATOS) completed its IPO in 2012.What are analysts saying about ATOS?
Atossa Therapeutics Inc. has had 1 recent analyst action on file. The most recent action was from Rodman & Renshaw: Buy with a $1200.00 price target on 2026-07-07. Recent price targets cluster around $1200.00.What companies are similar to ATOS?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare ATOS side-by-side with any of them on Quantisnow.How can I track ATOS on Quantisnow?
Quantisnow aggregates Atossa Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow ATOS to receive live email and push alerts on every new disclosure.